VEA
ODT

Virtus ETF Advisers’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Virtus ETF Advisers’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-19,421
Closed -$66K – 407
2021
Q1 		$66K Buy
19,421
+345
+2% +$6.52K 0.03% 354
2020
Q4 		$366K Buy
19,076
+10,941
+134% +$169K 0.15% 164
2020
Q3 		$109K Sell
8,135
-1,109
-12% -$31.4K 0.06% 319
2020
Q2 		$391K Sell
9,244
-3,166
-26% -$102K 0.19% 207
2020
Q1 		$343K Sell
12,410
-1,819
-13% -$53K 0.14% 210
2019
Q4 		$462K Buy
+14,229
New +$441K 0.08% 213

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Virtus ETF Advisers's ODT Position: Q2 2021 in Review

Virtus ETF Advisers sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q2 2021, closing a stake of 19,421 shares — an estimated $66K sold.

Virtus ETF Advisers first reported a position in ODT in Q4 2019 and held it in 6 quarters. The position peaked at $462K in Q4 2019. 69 funds tracked by Wall St. Rank hold ODT as of Q2 2021.

  • Virtus ETF Advisers reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Virtus ETF Advisers sold 19,421 Odonate Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $66K.
  • Virtus ETF Advisers first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2019 and held it in 6 quarters.
  • Virtus ETF Advisers's Odonate Therapeutics, Inc. Common Stock position peaked at $462K in Q4 2019.
  • 69 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.